Value of estrogenic recruitment before chemotherapy: First randomized trial in primary breast cancer

Journal of Clinical Oncology

Volumn 18, Issue 4, 2000, Pages 734-742

  Bontenbal, M ^a   Van Putten, W L J ^a   Burghouts, J Th M ^a   Baggen, M G A ^a   Ras, G J ^a   Stiegelis, W F ^a   Beudeker, M ^a   Janssen, J Th P ^a   Braun, J J ^a   van der Linden, G H M ^a   van der Velden, P C ^a   van Geel, A N ^a   Helle, P ^a   Leisink, M ^a   Foekens, J A ^a   Klijn, J G M ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN; ETHINYLESTRADIOL; FLUOROURACIL; STEROID RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TUMOR VOLUME;

EID: 0033984523     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.4.734     Document Type: Article

References (46)

1. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351:1451-1467, 1998
2. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352:930-942, 1998
3. Osborne CK, Boldt DH, Estrada P: Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res 44:1433-1439, 1984
4. Weichselbaum RR, Hellman S, Piro AJ, et al: Proliferation kinetics of a human breast cancer line in vitro following treatment with 17 beta-estradiol and 1-beta-D-arabinofuranosylcytosine. Cancer Res 38:2339-2342, 1978
5. Bontenbal M, Sieuwerts AM, Klijn JGM, et al: Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells. Br J Cancer 60:688-692, 1989
6. Clarke R, Van den Berg HW, Kennedy DJ, et al: Oestrogen receptor status and the response of human breast cancer cell lines to a combination of methotrexate and 17 beta-oestradiol. Br J Cancer 51:365-369, 1985
7. Hug V, Johnston D, Finders M, et al: Use of growth-stimulatory hormones to improve the in vitro therapeutic index of doxorubicin for human breast tumors. Cancer Res 46:147-152, 1986
8. Bontenbal M, Sonneveld P, Foekens JA, et al: Oestradiol enhances doxorubicin uptake and cytotoxicity in human breast cancer cells (MCF-7). Eur J Cancer Clin Oncol 24:1409-1414, 1988
9. Bontenbal M, Sieuwerts AM, Peters HA, et al: Manipulation of cell cycle kinetics: Influence on the cytotoxicity of doxorubicin in human breast cancer cells. J Steroid Biochem Mol Biol 37:1097-1101, 1990
10. Klijn JGM, Berns PMJJ, Bontenbal M, et al: Clinical breast cancer, new developments in selection and endocrine treatment of patients. J Steroid Biochem Mol Biol 43:211-221, 1992
11. Jordan VC: Chemotherapy is antihormonal therapy: How much proof do oncologists need? Eur J Cancer 34:606-608, 1998
12. Fisher B, Redmond C, Brown A, et al: Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1:227-241, 1983
13. Fisher B, Redmond C, Brown A, et al: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the national surgical adjuvant breast and bowel project trial. J Clin Oncol 4:459-471, 1986
14. Allegra JC: Methotrexate and 5-fluorouracil following tamoxifen and Premarin in advanced breast cancer. Semin Oncol 10:23-28, 1983 (suppl 2)
15. Lippman ME, Cassidy J, Wesley M, et al: A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization. J Clin Oncol 2:28-36, 1984
16. Paridaens R, Kiss R, Launoit Y, et al: Chemotherapy with estrogenic recruitment in breast cancer, in Klijn JGM, Paridaens R, Foekens JA (eds): Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti)Steroidal Agents. Monograph series of the European Organization for Research and Treatment of Cancer, vol 18, New York, NY, Raven Press, 1987, pp 477-486
17. Foekens JA, Portengen H, van Putten WLJ, et al: Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays. Cancer Res 49:5823-5828, 1989
18. Dao TL, Sinha DK, Nemoto T, et al: Effect of estrogen and progesterone on cellular replication of human breast tumors. Cancer Res 42:359-362, 1982
19. Miller WR: Estrogens and the normal breast, in Miller WR (ed): Estrogen and Breast Cancer. Heidelberg, Germany, Springer Verlag, 1996, pp 25-34
20. Conte PF, Alama A, Canavese G, et al: Cytokinetic effects of estrogens followed by chemotherapy in locally advanced human breast cancer. Cancer Immunol Immunother 18:16, 1984 (suppl) (abstr 62)
21. Conte PF, Alama A, Bertelli G, et al: Chemotherapy with estrogenic recruitment and surgery in locally advanced breast cancer: Clinical and cytokinetic results. Int J Cancer 40:490-494, 1987
22. Buzdar AV, Smith TL, Powell KC, et al: Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat 2:163-169, 1982
23. Cooper MR, Rhyne AL, Muss HB, et al: A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer. Cancer 47:2833-2839, 1981
24. Braunschweiger PG, Schiffer LM, Betancourt S: Tumor cell proliferation and sequential chemotherapy after partial tumor resection in C3H/HeJ mammary tumors. Breast Cancer Res Treat 2:323-329, 1982
25. Fisher B: NSABP trials: Reviews on Endocrine-Related Cancer 12:31-36, 1998 (suppl)
26. Epstein RJ, Smith PJ, Watson JV, et al: Characterisation of Vp-16-induced DNA cleavage in oestrogen stimulated human breast cancer cells. Br J Cancer 57:445-450, 1988
27. Epstein PJ: Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs. Cancer Res 48:297-303, 1988
28. Epstein RJ, Smith PJ, Watson JV, et al: Oestrogen potentiates topoisomerase-II-mediated cytotoxicity in an activated subpopulation of human breast cancer cells: Implications for cytotoxic drug resistance in solid tumours. Int J Cancer 44:502-505, 1989
29. Reed MJ, Ross MJ, Ghilchick MW: The effect of oestrogens and medroxyprogesterone acetate on the uptake of cytotoxic drugs by MCF-7 breast cancer cells. Anticancer Res 12:533-536, 1992
30. Bontenbal M, Sieuwerts AM, Peters HA, et al: Uptake and distribution of doxorubicin in hormone-manipulated human breast cancer cells in vitro. Breast Cancer Res Treat 51:139-148, 1998
31. Conte PF, Fraschini G, Alama A, et al: Chemotherapy following estrogen-induced expansion of the growth fraction of human breast cancer. Cancer Res 45:5926-5930, 1985
32. Fabian CJ, Kimler BF, McKittrick R, et al: Recruitment with high physiological doses of estradiol preceding chemotherapy: Flow cytometric and therapeutic results in women with locally advanced breast cancer - A Southwest Oncology Group study. Cancer Res 54:5357-5362, 1994
33. Santen RJ, Manni A, Harvey H, et al: Endocrine treatment of breast cancer in women. Endocrine Rev 11:221-265, 1990
34. Swain SM, Sorace RA, Bagley CS, et al: Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 47:3889-3894, 1987
35. Eisenhauer EA, Bowman DM, Pritchard KI, et al: Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer. Cancer Treat Rep 68:1421-1422, 1984
36. Benz C, Gandara D, Miller B, et al: Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: Endocrine pharmacokinetics and toxicity. Cancer Treat Rep 71:283-289, 1987
37. Hug V, Clark J, Johnston D: The results of modified use of chemotherapy for patients with metastatic breast cancer. Eur J Cancer 30A:438-442, 1994
38. Baldini E, Gardin G, Naso C, et al: Stimulation of human breast cancer in vivo: Experimental findings and clinical results. Ann N Y Acad Sci 698:418-422, 1993
39. Lipton A, Santen RJ, Harvey HA, et al: A randomized trial of aminoglutethimide ± estrogen before chemotherapy in advanced breast cancer. Am J Clin Oncol 10:65-70, 1987
40. Paridaens R, Heuson JC, Julien JP, et al: Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: A double-blind randomized study. J Clin Oncol 11:1723-1728, 1993
41. Conte PF, Pronzato P, Rubagotti A, et al: Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: Results of a randomized cooperative trial. J Clin Oncol 5:339-347, 1987
42. Conte PF, Baldini E, Gardin G, et al: Chemotherapy with or without estrogenic recruitment in metastatic breast cancer: A randomized trial of the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 7:487-490, 1996
43. Seymour L, Meyer K, Bezwoda WR: Hormone priming in breast cancer: Oestrogen priming has a detrimental effect on response inoestrogen receptor-negative patients. Eur J Cancer 29A:1495-1496, 1993
44. Ingle JN, Foley JF, Mailliard JA, et al: Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer. Cancer 73:2337-2343, 1994
45. Jancis EM, Carbone R, Loechner KJ, et al: Estradiol induction of rhodamine 123 efflux and the multidrug resistance pump in rat pituitary tumor cells. Mol Pharmacol 43:51-56, 1992
46. Teixeira C, Reed JC, Pratt MC: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55:3902-3907, 199526